What is Biogen's latest dividend and current dividend yield?

What were the key takeaways from Biogen's earnings call?

What were the key takeaways from Biogen’s earnings call?

What is Biogen's gross profit margin?

Did Biogen beat or miss consensus estimates last quarter?

What does Biogen do and what are its main business segments?

What guidance did Biogen's management provide for the next earnings period?

What factors drove the changes in Biogen's revenue and profit?

- **Growth Products Dominate**: 2025 growth products ($3.3B) outpaced MS decline, with LEQEMBI ($134M Q4 sales), ZURZUVAE, and VUMERITY leading.
- **Pipeline Momentum**: 10 Phase III programs, including litifilimab (SLE), felzartamab (AMR), and BIIB080 (tau ASO), set to deliver data in 2026-2027.
- **Strategic Acquisitions**: Alcyone Therapeutics to enhance SPINRAZA delivery; $2.1B free cash flow supports R&D and launches.
- **2026 Outlook**: Non-GAAP EPS $15.25-$16.25, revenue decline offset by growth products; lupus and nephrology launches key to future growth.

**【CEO Summary Section】**
- Biogen achieved strong Q4 and full-year 2025 performance, with growth products generating $3.3 billion (up 19% YoY) and legacy MS business contributing $3 billion.
- LEQEMBI maintained 60% market share in anti-amyloid therapy, with Q4 in-market sales of $134 million (up 54% YoY). IQLIK subcutaneous formulation under priority review in the U.S. with PDUFA date in May 2026.
- New products like ZURZUVAE and QALSODY drove $1 billion in revenue, while VUMERITY grew 19% YoY due to U.S. Part D redesign.
- Pipeline expansion includes litifilimab Phase III data in SLE (Q4 2026), felzartamab in AMR (2027), and SPINRAZA high-dose approval in the U.S. (April 2026). Acquisition of Alcyone Therapeutics to improve SPINRAZA delivery convenience.

**【CFO Financial Commentary】**
- Full-year 2025 non-GAAP EPS: $15.28 (vs. $14.83 in 2024). Q4 2025 non-GAAP EPS: $1.99, driven by strong growth products and cost control.
- Total revenue: $9.9 billion (up 2% YoY). Growth products (LEQEMBI, SKYCLARYS, SPINRAZA, VUMERITY) contributed $3.3 billion (up 9% YoY).
- U.S. MS business resilient, with TYSABRI and TACFIDERA showing resilience despite biosimilar competition.
- 2026 guidance: Non-GAAP EPS $15.25-$16.25, revenue decline mid-single digits due to MS erosion offset by growth products.

**【Q&A Highlights】**
- **LEQEMBI Growth**: CEO expects continued sequential growth, with 70% persistency rate post plaque removal. Subcutaneous IQLIK adoption depends on 2027 U.S. formulary decisions.
- **Top-line Growth**: CEO targets 2026 for growth products to overtake MS declines, citing litifilimab (SLE) and felzartamab (AMR) Phase III readouts.
- **BIIB080 (Tau ASO)**: Phase II data in early 2026 could validate tau hypothesis; potential to address Alzheimer's and other tauopathies.
- **Lupus Pipeline**: Litifilimab Phase III in SLE (Q4 2026) and CLE (mid-2027) with BDCA2 pathway targeting type 1 interferon response.
- **SPINRAZA High-Dose**: U.S. approval in April 2026; Japan launch shows higher efficacy and faster motor function recovery.
- **Commercial Strategy**: Reallocating resources from legacy MS to lupus, nephrology, and rare disease launches; no immediate share buyback plans.

Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript

- **Launch Product Dominance**: LEQEMBI (+82% global sales) and ZURZUVAE (+19% U.S. growth) drive 67% YoY revenue increase in launch portfolio.
- **Pipeline Momentum**: 10 Phase III programs, including Felzartamab (80% AKI resolution in lupus) and BIIB080 (tau ASO with potential combination therapies).
- **Immunology Focus**: Strategic shift to rare immunology with 25%+ pipeline allocation, leveraging MS expertise in kidney and lupus indications.
- **Financial Strength**: $1.2B free cash flow, $4B cash balance, and on-track $1B gross savings target.
- **Access Expansion**: LEQEMBI subcutaneous maintenance approved in 34 countries, Sky Claris launched in 34 markets with 50%+ new writers.

**【CEO Summary Section】**
- Biogen reported strong third-quarter performance, with launch products contributing $257 million in revenue, up 67% year-over-year. Key growth drivers include LEQEMBI (82% global revenue growth) and ZURZUVAE (19% U.S. revenue growth). 
- Emphasized strategic focus on immunology, with 10 Phase III programs in rare disease and kidney indications. CEO highlighted Felzartamab's Phase II data showing 80% resolution of acute kidney injury in lupus patients.
- Reaffirmed commitment to disciplined capital allocation, with $1.2 billion free cash flow and $4 billion in cash reserves.

**【CFO Financial Commentary】**
- Q3 non-GAAP diluted EPS of $1.08, up 18% year-over-year, driven by launch product growth and cost management.
- U.S. MS business resilient despite generic erosion in Europe, with subcutaneous Tysabri maintaining 50% market share.
- Full-year guidance updated to reflect stronger business trends, with $1.2 billion gross savings target on track.

**【Q&A Highlights】**
- LEQEMBI subcutaneous maintenance: Positive feedback from HCPs on ease of use, with 10,000+ infusions completed. Medicare Part D coverage expected by 2027.
- Sky Claris: 30% year-over-year growth, with 34 global launches and 80%+ new prescriptions from first-time writers.
- Alzheimer's pipeline: Phase III litifilimab readouts expected in 2026, with potential for combination therapies with anti-tau ASO BIIB080.
- ZURZUVAE: 19% increase in prescribing breadth, with 55% of scripts from PCPs in Q3.


Biogen (BIIB)-30 Oct 25-2025 Q3 Earnings call transcript

- **Revenue Beat**: 7% YoY growth driven by $252M launch products, offsetting MS decline.
- **Product Momentum**: LEQEMBI U.S. growth 20% QoQ; ZURZUVAE 68% QoQ; SKYCLARYS 5% global growth.
- **Pipeline Breakthroughs**: Salanersen SMA Phase Ib shows motor milestone achievements; felzartamab Phase III for IgAN and MVI.
- **Financial Strength**: Raised 2025 EPS guidance to $15.50-$16; $134M free cash flow; $1B Fit for Growth savings on track.
- **Strategic Differentiation**: Subcutaneous LEQEMBI PDUFA in August; lupus pipeline Phase III expansion.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 revenue grew 7% YoY, driven by launch products (VUMERITY, LEQEMBI, SKYCLARYS, ZURZUVAE) generating $252M, offsetting MS decline. U.S. MS business remained resilient with $657M in revenue.
- **Product Highlights**: VUMERITY grew due to market exclusivity; LEQEMBI saw 20% QoQ growth in the U.S.; SKYCLARYS expanded to 29 markets; ZURZUVAE grew 68% QoQ.
- **Pipeline Progress**: Felzartamab Phase III studies initiated; salanersen showed promise in SMA with motor function improvements; lupus pipeline includes dapirolizumab and litifilimab Phase III trials.
- **Strategic Moves**: $1.75B debt refinancing to support growth; Fit for Growth initiative on track for $1B gross savings.

**【CFO Financial Commentary】**
- **Financial Performance**: Non-GAAP EPS of $5.73 (excluding $0.26 impact from IPR&D), up 9% YoY. Full-year 2025 guidance raised to $15.50-$16 EPS.
- **Cost Management**: Core operating expenses down 2% YoY; $47M in acquired IPR&D charges (City Therapeutics, felzartamab milestone).
- **Cash Flow**: $134M free cash flow; $2.8B cash on hand, supporting R&D and manufacturing investments.

**【Q&A Highlights】**
- **LEQEMBI Competition**: Maintains 70% U.S. market share; subcutaneous formulation PDUFA date in August; direct-to-consumer campaign boosts demand.
- **SMA Dynamics**: Salanersen Phase III expected in 2028; myostatin therapies seen as additive, not competitive.
- **Lupus Pipeline**: Dapirolizumab Phase III data anticipated in 2027; litifilimab targeting type 1 interferon pathway.
- **Eisai Partnership**: Strong collaboration despite European commercialization arbitration; LEQEMBI subcutaneous convenience differentiates from donanemab.
- **Blood Biomarkers**: Usage tripled YoY; CMS reimbursement clarity needed for broader adoption.


Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript

- **Rare Disease Growth Engine**: 45% of revenue from ZURZUVAE, LEQEMBI, and VUMERITY, with SKYCLARYS up 59% YoY.
- **LEQEMBI Momentum**: $96M Q1 sales, EU approval, and SC formulation approvals in H2 2025 to drive convenience.
- **Pipeline Acceleration**: BIIB080 (Fast Track for Alzheimer's) and felzartamab Phase 3 trials in AMR/IgAN.
- **Financial Resilience**: $2.4B Q1 revenue (+6% YoY), $222M free cash flow, minimal tariff impact in 2025.
- **Strategic Shifts**: Moving from MS to rare disease leadership, with disciplined pipeline expansion via preclinical collaborations.


**【CEO Opening Remarks】**
- Biogen is transitioning from an MS-focused company to a rare disease and neurology leader, with 45% of product revenue now from ZURZUVAE, LEQEMBI, and VUMERITY.
- LEQEMBI achieved $96M in Q1 sales, up 11% QoQ, with EU approval and subcutaneous (SC) formulation approvals expected in H2 2025 to simplify administration.
- SKYCLARYS grew 59% YoY to $124M, driven by global expansion and rare disease patient identification strategies.
- Pipeline highlights include BIIB080 (Fast Track for Alzheimer's) and felzartamab Phase 3 trials in AMR and IgAN.
- Tariffs pose minimal 2025 impact due to U.S.-based manufacturing (75% of 2024 U.S. revenue from domestic plants) and inventory buffers.

**【CFO Financial Update】**
- Q1 2025 revenue: $2.4B (+6% YoY), with launch products contributing $200M (+22% QoQ).
- Non-GAAP EPS: $3.02 (-18% YoY), impacted by $165M Stoke upfront payment. Excluding this, EPS would have been $3.97 (+8% YoY).
- Free cash flow: $222M, ending with $2.6B cash.
- MS franchise decline: 11% YoY due to biosimilar competition, offset by VUMERITY growth.
- Full year 2025 guidance: EPS $14.50-$15.50, revenue down mid-single digits due to MS decline.

**【Key Q&A Highlights】**
- **LEQEMBI Europe Strategy**: Eisai leading local launches, focusing on early access programs and regulatory alignment across EU markets.
- **SC Formulation Impact**: Maintenance SC dosing approved, initiation SC expected H1 2026, reducing infusion center dependency.
- **Competitor Dynamics**: Donanemab and LEQEMBI targeting different patient segments; Biogen focuses on early treatment and long-term adherence.
- **Business Development**: Seeking preclinical collaborations (4-5/year) to diversify pipeline beyond late-stage M&A.
- **FDA Engagement**: Positive feedback on rare disease endpoints; Dravet Phase 3 design aligned with Stoke partner.
- **Manufacturing**: U.S. plants at ~80% utilization, open to CDMO partnerships for excess capacity.


Biogen (BIIB)-1 May 25-2025 Q1 Earnings call transcript

- **Revenue Resilience**: Q4 2024 revenue of $2.5B and full-year EPS growth of 12% highlight Biogen's ability to offset MS decline with new product momentum.
- **LEQEMBI Acceleration**: 30% QoQ growth in Q4, with subcutaneous dosing and blood diagnostics set to drive 2025 expansion.
- **Pipeline Potential**: Alzheimer's pipeline (AHEAD 3-45 trial) and immunology assets (e.g., dapirolizumab) position Biogen for long-term growth.
- **Cost Efficiency**: $2.7B free cash flow in 2024 and $3.9B 2025 OpEx target reflect successful Fit for Growth initiatives.
- **Strategic Flexibility**: $200M Royalty Pharma funding and disciplined M&A approach support future innovation.


**【CEO Summary Section】**
- Biogen's revenue for Q4 2024 was $2.5 billion, with non-GAAP EPS of $3.44, up 17% YoY. The MS portfolio decline was offset by growth in new products like SKYCLARYS and LEQEMBI.
- Key strategic priorities include advancing the pipeline (e.g., Alzheimer's, immunology), reducing operating expenses, and investing in growth. The pipeline is expected to surpass the current biopharma business in peak sales.
- LEQEMBI showed 30% sequential growth in Q4, with U.S. sales at $50 million. Subcutaneous maintenance dosing is expected in H2 2025, and a presymptomatic trial (AHEAD 3-45) is fully enrolled.

**【CFO Financial Commentary】**
- Full year 2024 revenue was $9.7 billion (-2% YoY), with non-GAAP EPS of $16.47 (+12% YoY). Free cash flow improved to $2.7 billion (+$1.4 billion YoY) due to cost savings and strong operating income.
- MS product revenue declined 8% QoQ, driven by biosimilar and generic competition. Rare disease revenue grew 15% QoQ, led by SKYCLARYS (+83% YoY) and SPINRAZA (+6% YoY in the U.S.).
- 2025 guidance: Non-GAAP EPS of $15.25-$16.25, with a mid-single-digit revenue decline due to MS erosion, partially offset by new product growth. Operating expenses are expected to stabilize at $3.9 billion.

**【Q&A Key Highlights】**
- **Pipeline & External BD**: CEO emphasized internal pipeline strength but noted potential for disciplined external deals. Royalty Pharma funding ($200M in 2025) will reduce R&D expenses. 
- **LEQEMBI Growth**: Blood-based diagnostics and subcutaneous formulations could accelerate uptake. AHEAD 3-45 trial enrollment is complete, with results expected in 2028.
- **SKYCLARYS Dynamics**: U.S. growth challenges include patient identification and reimbursement. Ex-U.S. expansion (e.g., Latin America) is a key driver. 
- **SPINRAZA Strategy**: High-dose option approval expected in 2025, with a port delivery device in development for 2026.
- **Financial Flexibility**: $2.4 billion cash balance and strong free cash flow support investments in growth and M&A.


Actual																	9.14	10.26	8.84	4.58	5.34	5.68	4.77	3.39	3.62	5.25	4.77	4.05	3.4	4.02	4.36	2.95	3.67	5.28	4.08	3.44	3.02	5.47	4.81	1.99
Forecast																	7.7242	8.0221	8.0863	4.7917	4.9815	4.5491	4.0862	3.377	4.3401	4.0602	4.1258	3.4891	3.2782	3.7765	3.9735	3.184	3.4695	4.068	3.7724	3.3313	2.8993	3.8986	3.8824	1.6251
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+18.33%	+27.90%	+9.32%	-4.42%	+7.20%	+24.86%	+16.73%	+0.38%	-16.59%	+29.30%	+15.61%	+16.08%	+3.72%	+6.45%	+9.73%	-7.35%	+5.78%	+29.79%	+8.15%	+3.26%	+4.16%	+40.31%	+23.89%	+22.45%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	3.53B	3.68B	3.38B	2.85B	2.69B	2.77B	2.78B	2.73B	2.53B	2.59B	2.51B	2.54B	2.46B	2.46B	2.53B	2.39B	2.29B	2.46B	2.47B	2.45B	2.43B	2.65B	2.53B	2.28B
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	3.42B	3.43B	3.33B	2.80B	2.65B	2.61B	2.67B	2.62B	2.50B	2.47B	2.47B	2.45B	2.34B	2.37B	2.40B	2.47B	2.31B	2.39B	2.43B	2.41B	2.23B	2.33B	2.34B	2.20B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+3.25%	+7.34%	+1.24%	+2.00%	+1.64%	+6.35%	+4.11%	+4.34%	+1.28%	+4.66%	+1.60%	+4.04%	+5.18%	+3.77%	+5.44%	-3.23%	-0.80%	+3.03%	+1.29%	+1.93%	+8.81%	+13.63%	+8.32%	+3.46%

BIIB

BIIB fundamentals

BIIB Q4 2025 Earnings

Earnings Call

You can ask Aime

BIIB

BIIB fundamentals

BIIB Q4 2025 Earnings

Earnings Call

BIIB Earnings Call Summary for Q4/20258:30 AM on Feb 6, 2026

BIIB Earnings Call Summary for Q3/20258:30 AM on Oct 30, 2025

BIIB Earnings Call Summary for Q2/20258:00 AM on Jul 31, 2025

BIIB Earnings Call Summary for Q1/20258:30 AM on May 1, 2025

BIIB Earnings Call Summary for Q4/20248:30 AM on Feb 12, 2025

You can ask Aime